Appili Therapeutics – Press Release Correction
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) has issued a correction to its October 10, 2024 press release regarding the proposed arrangement with Aditxt, Inc. The initial press release incorrectly stated the cash consideration for each Appili share as US$ 0.467. The correct cash amount is US$ 0.0467 per Appili Share.
Under the corrected terms of the arrangement, for each Class A common share of Appili, shareholders will receive:
- US$ 0.0467 in cash
- 0.0000686251 of a share of Aditxt common stock (valued at approximately US$0.00013 per Appili Share based on Aditxt's closing price on October 3, 2024)
This correction is significant as it substantially reduces the cash component of the consideration for Appili shareholders in the proposed arrangement with Aditxt, Inc.
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) ha emesso una correzione al comunicato stampa del 10 ottobre 2024 riguardante l'accordo proposto con Aditxt, Inc. Il comunicato iniziale indicava erroneamente la somma in contanti per ciascuna azione Appili come US$ 0,467. La somma corretta è di US$ 0,0467 per azione Appili.
Secondo i termini corretti dell'accordo, per ogni azione ordinaria di Classe A di Appili, gli azionisti riceveranno:
- US$ 0,0467 in contanti
- 0,0000686251 di un'azione ordinaria di Aditxt (valutata approssimativamente a US$ 0,00013 per azione Appili basata sul prezzo di chiusura di Aditxt del 3 ottobre 2024)
Questa correzione è significativa in quanto riduce sostanzialmente la componente in contanti della considerazione per gli azionisti Appili nell'accordo proposto con Aditxt, Inc.
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) ha emitido una corrección a su comunicado de prensa del 10 de octubre de 2024 sobre el arreglo propuesto con Aditxt, Inc. El comunicado inicial indicaba incorrectamente la cantidad en efectivo por cada acción de Appili como US$ 0.467. La cantidad correcta en efectivo es US$ 0.0467 por acción de Appili.
Bajo los términos corregidos del arreglo, por cada acción ordinaria de Clase A de Appili, los accionistas recibirán:
- US$ 0.0467 en efectivo
- 0.0000686251 de una acción ordinaria de Aditxt (valorada aproximadamente en US$ 0.00013 por acción de Appili según el precio de cierre de Aditxt el 3 de octubre de 2024)
Esta corrección es significativa ya que reduce sustancialmente el componente en efectivo de la consideración para los accionistas de Appili en el arreglo propuesto con Aditxt, Inc.
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF)가 Aditxt, Inc.와의 제안된 협약에 대한 2024년 10월 10일 보도 발표에 대한 수정을 발표했습니다. 초기 보도 자료에서는 각 Appili 주식의 현금 보상이 잘못 기재되어 US$ 0.467로 명시되었습니다. 정확한 현금 금액은 Appili 주식당 US$ 0.0467입니다.
수정된 협약 조건에 따라, Appili의 A 클래스 보통주당 주주들은 다음을 받게 됩니다:
- US$ 0.0467의 현금
- 0.0000686251의 Aditxt 보통주 (2024년 10월 3일 Aditxt의 종가를 기준으로 약 US$ 0.00013로 평가됨)
이 수정은 Aditxt, Inc.와의 제안된 협약에 따라 Appili 주주를 위한 현금 요소를 실질적으로 감소시키기 때문에 중요합니다.
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) a émis une correction à son communiqué de presse du 10 octobre 2024 concernant l'arrangement proposé avec Aditxt, Inc. Le communiqué initial indiquait par erreur que la contrepartie en espèces pour chaque action Appili était de 0,467 USD. Le montant correct en espèces est de 0,0467 USD par action Appili.
Selon les termes corrigés de l'arrangement, pour chaque action ordinaire de Classe A d'Appili, les actionnaires recevront :
- 0,0467 USD en espèces
- 0,0000686251 d'une action ordinaire d'Aditxt (évaluée à environ 0,00013 USD par action Appili en fonction du prix de clôture d'Aditxt du 3 octobre 2024)
Cette correction est significative puisqu'elle réduit considérablement la composante en espèces de la contrepartie pour les actionnaires d'Appili dans l'arrangement proposé avec Aditxt, Inc.
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) hat eine Korrektur zu seiner Pressemitteilung vom 10. Oktober 2024 bezüglich des vorgeschlagenen Arrangements mit Aditxt, Inc. herausgegeben. In der ursprünglichen Pressemitteilung wurde das Barentgelt für jede Appili-Aktie fälschlicherweise mit US$ 0,467 angegeben. Der korrekte Barbetrag beträgt US$ 0,0467 pro Appili-Aktie.
Unter den korrigierten Bedingungen des Arrangements erhalten die Aktionäre für jede Klasse A Stammaktie von Appili:
- US$ 0,0467 in bar
- 0,0000686251 einer Stammaktie von Aditxt (geschätzt auf etwa US$ 0,00013 pro Appili-Aktie basierend auf dem Schlusskurs von Aditxt am 3. Oktober 2024)
Diese Korrektur ist signifikant, da sie den Baranteil der Gegenleistung für die Appili-Aktionäre im vorgeschlagenen Arrangement mit Aditxt, Inc. erheblich reduziert.
- None.
- Cash consideration for Appili shareholders reduced from US$ 0.467 to US$ 0.0467 per share
- Total value of consideration per Appili share (cash + stock) decreased to approximately US$ 0.047 from US$ 0.467
HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled “Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders” issued on October 10, 2024 (the “Initial Press Release”).
The Initial Press Release, incorrectly stated that under the terms of the proposed arrangement with Aditxt, Inc. (the “Arrangement”), for each Class A common share of the Company (“Appili Shares”), shareholders will receive (i) US
This press release should be read in conjunction with the Initial Press Release and is subject to the forward looking statement disclaimer set out in the Initial Press Release. These corrections do not change any other information reported in the Initial Press Release.
Media Contact:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:
Don Cilla, President and CEO
Appili Therapeutics
E: Info@AppiliTherapeutics.com
FAQ
What is the corrected cash consideration for Appili Therapeutics (APLIF) shareholders in the Aditxt arrangement?
How much Aditxt stock will Appili Therapeutics (APLIF) shareholders receive in the arrangement?
What is the total value of consideration per Appili Therapeutics (APLIF) share in the corrected arrangement terms?
When did Appili Therapeutics (APLIF) announce the correction to its press release about the Aditxt arrangement?
